IART — Integra Lifesciences Holdings Corp

★

IART

Integra Lifesciences Holdings Corp · Health Care

FCF$4mC-

Rev+1.2%C

D/E0.17A-

P/S0.7xA

PEG——

66Score

$15.10

1Y Target$20.39Near-term target

5Y Target$30.37Compound horizon

10Y Target$79.03Long-dated conviction

FCF$4mTTM · 03/26

C-

FCF $4m — barely positive; fragile cash position · TTM computed from 4 most-recent quarters (TTM · 03/26).

Rev+1.2%TTM YoY

Revenue +1.2% — flat, mature phase or headwinds present · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.

D/E0.17total

A-

D/E 0.17 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.

P/S0.7x

P/S 0.7x — deep value on sales

PEG—proxy

—

PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).

Why now

Health Care · market cap $1.2b. 8% off the 52-week high of $16.49.

Moat

Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.

Risk

Currently unprofitable (margin -30.1%) — path to GAAP profitability is the core thesis risk. ROE -48% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.

Horizon

1-3 yr $20.39 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $30.37 — requires the platform / technology to reach commercial scale. 10 yr $79.03 — return distribution heavily skewed.

Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Position sizing · IART

Portfolio

Risk per trade

Stop loss below entry

Shares to buy

132

Position size

$1,993

4.0% of portfolio

Stop price

$11.32

25% below $15.10

$ at risk

$500.00

1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Analyze another ticker →